ReviewPathologica2019
When tumor doesn't read textbook. Third case of TTF1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?
Review in Pathologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Diffuse co-expression of TTF-1 and p40 (ΔNp63) defines a distinct biphenotypic non-small cell lung carcinoma: clinicopathologic and molecular characterization of 19 cases.Diagnostic pathology · 2026Article
- Non-small cell lung carcinoma with co-expression of thyroid transcription factor-1 and p40: a case report and literature review.World journal of surgical oncology · 2025Review
- TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequentTranslational lung cancer research · 2025Article
- TTF-1 and p40 co-expressing non-small cell lung cancer with ERBB2 and TP53 gene mutations: A case report and review of the literature.Medicine · 2025Review
- Non-small cell lung carcinoma with focal coexpression of thyroid transcription factor-1 and Δ Np63/p40: A case report.Thoracic cancer · 2024Article
- Review
- P40 and TTF-1 double-expressing non-small cell lung cancer with EML4-ALK and PIK3CA gene mutations: A case report and review of the literature.Oncology letters · 2023Article
- Liver X receptors and estrogen receptor β, two players in a rare subtype of NSCLC.International journal of biological sciences · 2023Article
- Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.Histopathology · 2023Article
- Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq.Genome medicine · 2022Article
- Article
- Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations.JTO clinical and research reports · 2021Article
- Cell-blocks and immunohistochemistry.CytoJournal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe 2011 WHO Classification for lung adenocarcinoma enlightened the need for a wise use of immunohistochemistry to preserve tissue for both diagnosis and molecular studies. The current recommendation is to use a panel comprising TTF1 and p40 to classify tumors with no clear squamous or glandular differentiation as many studies have showed the higher specificity of p40 over p63 as marker of squamous differentiation. However, the co-expression of both markers opens a new scenario with subsequent classification and potentially treatment issues. MATERIALS AND
methodsWe report a case of a non-small lung cell carcinoma (NSCLC) with coexistent expression of TTF1 and p40 in the same tumour cells. To our knowledge, this peculiar immunohistochemical profile is very rare, and thus a review of the clinical and molecular features including molecular variances of the tumour was performed. Review of the pertinent literature was also carried out.
resultsTwo additional articles describing unusual cases of NSCLC with coexistent expression of TTF1 and p40 were found and compared to our case. Interestingly, they all carried out aberrant mutation in TP53 oncogene and were of advance stage.
conclusionThe positivity for both "squamous" and "adenocarcinomatous" markers and mutations of TP53 could be the expression of a not fully recognized variant of NSCLC with possible implications for classification, diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.